The incidence of this drug-induced lupus
is dose dependent and has been reported to occur in 5.4% of
patients receiving 100 mg of hydralazine daily and in 10.4%
of those receiving 200 mg daily, with a slightly higher incidence in women than in men.75
Fortunately, the clinical
manifestations of the syndrome (arthralgias, glomerulonephritis) resolve when the drug is discontinued.